Found: 15
Select item for more details and to access through your institution.
Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 68
- By:
- Publication type:
- Article
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 65
- By:
- Publication type:
- Article
Anito-Cel Yields 100% Response Rate in R/R Myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Proceeding
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 46
- By:
- Publication type:
- Article
Lawmaker Says Consumers Want and Need Price Transparency in Health Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 44
- By:
- Publication type:
- Article
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 43
- By:
- Publication type:
- Article
NEW ADVANCES IN Waldenström Macroglobulinemia.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 38
- By:
- Publication type:
- Article
MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 32
- By:
- Publication type:
- Article
Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 28
- By:
- Publication type:
- Article
Novel Therapies and Combinations Augment Melanoma Treatment Arsenal.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 25
- By:
- Publication type:
- Article
Combination Regimens Make Their Mark in Frontline HCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 16
- By:
- Publication type:
- Article
Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2- Breast Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Interview
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 8
- Publication type:
- Article
THE ONGOING DEBATE: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 6
- By:
- Publication type:
- Article
Advancements Roll in Across Tumor Types as Conference Season Continues.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 4
- By:
- Publication type:
- Article